Physician profile
Robert M Lind
NPI 1235244674
$31,899.21
in general payments reported to CMS, 2019-2025
68 companies · $623 in 2025
The $623 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $4,518 · 2021: $2,735 · 2022: $2,340 · 2023: $7,865 · 2024: $2,570 · 2025: $623.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $5,880 · Food and Beverage: $5,129 · Education: $48.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $5,880.00 |
| Food and Beverage | $5,129.43 |
| Education | $48.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $10,223.59 | 2019-2025 | Omnipod |
| Novo Nordisk INC | $8,179.91 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $2,902.54 | 2019-2023 | Farxiga, Lokelma |
| Lilly USA, LLC | $1,058.62 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $818.66 | 2019-2024 | |
| Amgen INC. | $773.44 | 2019-2025 | Evenity, Prolia, Repatha |
| Mannkind Corporation | $680.89 | 2019-2025 | Afrezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $663.58 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Amneal Pharmaceuticals LLC | $643.68 | 2019-2025 | Unithroid |
| Antares Pharma, INC. | $566.13 | 2019-2024 | Xyosted, Tlando, Nocdurna |
| Corcept Therapeutics | $435.08 | 2019-2024 | Korlym |
| Pfizer INC. | $371.84 | 2019-2025 | |
| Abbott Laboratories | $323.70 | 2019-2024 | Freestyle Libre |
| Tandem Diabetes Care, INC. | $307.70 | 2019-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Recordati_rare_diseases_inc. | $250.49 | 2020-2024 | Isturisa, Signifor Lar |
Show all 68 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Lind listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.